Maximum Standardized Uptake Value on 18F-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography and Glucose Transporter-1 Expression Correlates With Survival in Invasive Ductal Carcinoma of the Pancreas

Objectives The purpose of this study was to assess the correlations among the maximum standardized uptake value (SUVmax) on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT); the expressions of glucose transporter 1 (GLUT-1), glucose transporter 3, and epidermal growth factor receptor (EGFR); as well as prognosis in patients with invasive ductal carcinoma of the pancreas. Methods A total of 41 patients with surgically resected and histologically proven invasive ductal carcinoma of the pancreas who underwent preoperative FDG-PET/CT were assessed. The SUVmax at the primary tumor site was measured by FDG-PET/CT, and immunohistochemical staining of tumor sections was performed for GLUT-1, glucose transporter 3, and EGFR. Results Higher FDG uptake (SUVmax, >3.40) and GLUT-1 expression were significantly associated with shorter overall survival (P < 0.05). The SUVmax was not found to be significantly correlated with clinicopathological characteristics such as TNM classification, lymph node metastasis, and tumor differentiation. The EGFR expression was significantly correlated with the SUVmax (P = 0.024). Conclusions Higher FDG uptake and GLUT-1 expression in invasive ductal carcinoma of the pancreas seems to be an important prognostic factor. In addition, the EGFR expression was significantly correlated with the SUVmax.

[1]  P. Bie,et al.  Pancreaticoduodenectomy Combined with Vascular Resection and Reconstruction for Patients with Locally Advanced Pancreatic Cancer: A Multicenter, Retrospective Analysis , 2013, PloS one.

[2]  Jai-Hyuen Lee,et al.  Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma. , 2012, Nuclear medicine and biology.

[3]  Masao Tanaka,et al.  Japan Pancreatic Cancer Registry; 30th Year Anniversary: Japan Pancreas Society , 2012, Pancreas.

[4]  Stephen C Peiper,et al.  Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma , 2012, Cancer.

[5]  C. Willett,et al.  Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? , 2012, Journal of surgical oncology.

[6]  T. Nakajima,et al.  Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. , 2012, European journal of cancer.

[7]  C. Onal,et al.  Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy , 2012, Radiation oncology.

[8]  O. Basturk,et al.  GLUT-1 Expression in Pancreatic Neoplasia: Implications in Pathogenesis, Diagnosis, and Prognosis , 2011, Pancreas.

[9]  Yukiko Nakamura,et al.  Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Y. Hasegawa,et al.  FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma. , 2009, Oral oncology.

[11]  A. Mehrabi,et al.  Vascular Resection in Pancreatic Cancer Surgery: Survival Determinants , 2009, Journal of Gastrointestinal Surgery.

[12]  Jun Liu,et al.  Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. , 2007, International journal of oncology.

[13]  Sigrid Stroobants,et al.  The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer , 2007 .

[14]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.

[16]  R. Cerfolio,et al.  The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. , 2005, The Journal of thoracic and cardiovascular surgery.

[17]  S. Ashley,et al.  Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. , 2004, Surgery.

[18]  Hidetaka Mochizuki,et al.  The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness: Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2004, Pancreas.

[19]  T. Saga,et al.  Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  H. Friess,et al.  Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. , 1999, Annals of surgery.

[21]  Y. Nio,et al.  Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. , 1998, Anticancer research.

[22]  H. Sakahara,et al.  FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  S. Gansauge,et al.  Prognostic significance of molecular alterations in human pancreatic carcinoma – an immunohistological study , 1998, Langenbeck's Archives of Surgery.

[24]  Y. Nio,et al.  Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. , 1997, Anticancer research.

[25]  D. Klimstra,et al.  Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. , 1996, Annals of surgery.

[26]  M. Younes,et al.  Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. , 1996, Cancer research.

[27]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[28]  S. Digumarthy,et al.  Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. , 2011, The oncologist.

[29]  H. Matsuda,et al.  Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection , 2011, International Journal of Clinical Oncology.

[30]  S. Saglam,et al.  Long-term survival after curative resection for pancreatic ductal adenocarcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Ellis,et al.  Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.